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The blood pressure eﬀect and related plasma
levels of ﬂavan-3-ols in spontaneously
hypertensive rats
Mar Quiñones,*†a Maria Margalef,b Anna Arola-Arnal,b Begoña Muguerza,*b,c
Marta Migueld and Amaya Aleixandrea
We studied the short-term antihypertensive eﬀect of ﬂavan-3-ols (−)-epicatechin, (+)-catechin and
(−)-catechin, in spontaneously hypertensive rats (SHR). Plasma metabolites and the corresponding plasma
antioxidant capacity were determined. All the assayed ﬂavan-3-ols decreased systolic blood pressure
(SBP) in SHR. Their antihypertensive eﬀects were less pronounced than that of Captopril (50 mg kg−1) and
were not shown in normotensive Wistar-Kyoto rats. 6 mg kg−1 (−)-epicatechin caused the maximum
decrease in SBP. The maximum eﬀects of the catechin monomers were observed post-administration of
0.5 mg kg−1 of ﬂavan-3-ols, (−)-catechin being the least eﬀective among the three assayed compounds.
Glucuronide and methyl glucuronide metabolites were obtained in the ﬂavan-3-ol treated SHR, but it was
not possible to relate the antihypertensive eﬀect of the assayed ﬂavan-3-ols with a concrete plasma
metabolite or with their antioxidant eﬀect. In conclusion, the studied ﬂavan-3-ols could be responsible
for the antihypertensive eﬀect of cocoa products.
1. Introduction
In recent years, numerous studies have demonstrated the health
benefits of polyphenols, and special attention has been paid to
their beneficial eﬀect on hypertension and cardiovascular
diseases.1–3 In particular, flavan-3-ols, also known as flavanols,
are the most structurally complex subclass of flavonoids, and
have been recognized as antihypertensive agents.1,4 These com-
pounds are present in diﬀerent foods such as cocoa, grape, tea,
apple and berries.5 Cocoa, in particular, has a high content in
flavan-3-ols.6,7 Elegant reports have shown the beneficial eﬀect
of cocoa on blood pressure.6,8 Moreover, our research group
demonstrated that a polyphenol enriched cocoa powder showed
antihypertensive properties,9 improved endothelial function,10
and exhibited an antioxidant capacity.11
Cocoa flavan-3-ols consist of a complex mixture of the
monomeric (−)-epicatechin and (+)-catechin and the oligomers
of these monomeric base units known as procyanidins.5 It is
nevertheless worth nothing that the preservation of flavan-3-
ols during cocoa manufacturing is important to exhibit the
health eﬀects associated with cocoa consumption, and it has
been recently described that roasted cocoa beans and cocoa
products additionally contained (−)-catechin. This atypical
flavan-3-ol is generally formed during the cocoa manufactur-
ing process by an epimerization which converts (−)-epicatechin
to its epimer (−)-catechin. High temperatures during the cocoa
bean roasting process, and particularly the alkalization of the
cocoa powder, are the main factors inducing the epimerization
reaction.12
The bioavailability of flavan-3-ols is higher than the bio-
availability of other flavonoids, even if it is also relatively
poor.13 Moreover, flavan-3-ols, as other kinds of flavonoids,
occur in plasma in more diverse forms than in food.14,15 In
fact, the uptake and metabolism of polyphenols are usually
associated with their methylation, sulphation or glucuronida-
tion, aﬀorded by phase-II enzymes.16 In addition, considerable
quantities of ingested flavonoids are degraded by colonic
microbiota upon reaching the large intestine, where they yield
other smaller molecules that are also absorbed into the
body.17 Therefore, the identification of the specific flavan-3-ol
metabolites present in the body is crucial for understanding
their biological activities.
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Diﬀerent studies have demonstrated that (−)-epicatechin,
(+)-catechin and their oligomers, have important cardiovascular
beneficial eﬀects, such as the ability to inhibit LDL oxidation18
and the capacity to promote endothelium-dependent relax-
ation.19 Moreover these compounds can also modulate the pro-
duction of inflammatory cytokines20 and can inhibit pro-
inflammatory response in in vitro systems.21 Nevertheless,
scarce research exists for evaluating the short-term antihyper-
tensive eﬀect of the main cocoa flavan-3-ols. The aim of this
study was to characterize the dose dependent short-term anti-
hypertensive eﬀect of (−)-epicatechin, (+)-catechin and the aty-
pical flavan-3-ol (−)-catechin, in spontaneously hypertensive
rats (SHR). The corresponding plasma flavan-3-ol compound
and its main metabolites in this fluid were quantified. More-
over, since the antioxidant eﬀect of polyphenols enables us to
explain many of their health benefits, the corresponding
plasma antioxidant eﬀect was also determined.
2. Materials and methods
2.1. Chemicals and reagents
Captopril, (−)-epicatechin, (+)-catechin and (−)-catechin were
used for the experiments, and all these compounds were pur-
chased from Sigma Chemical (Fluka/Sigma Aldrich, Madrid,
Spain). Captopril was dissolved in water to be administered to
the rats. (+)-Catechin, (−)-catechin and (−)-epicatechin were
prepared with 10% DMSO in water and sonicated for
45 minutes before administration to the animals.
For the chromatographic analysis, methanol (Scharlab S.L.,
Barcelona, Spain), acetone (Sigma-Aldrich, Madrid, Spain) and
glacial acetic acid (Panreac, Barcelona, Spain) of HPLC analyti-
cal grade, were used. Ultrapure water was obtained from a
Milli-Q advantage A10 system (Madrid, Spain). The 2000 mg
l−1 standard stock solutions of (+)-catechin, (−)-epicatechin
and pyrocatechol (Sigma Aldrich, Madrid, Spain) in methanol
as the internal standard (IS), were stored in dark-glass
flasks at −20 °C. A 200 mg l−1 stock standard mixture of
(+)-catechin and (−)-epicatechin was prepared weekly and
stored at −20 °C. The stock standard solution was diluted daily
to the desired concentration using an acetone : water : acetic
acid (70 : 29.5 : 0.5, v : v : v) solution.
2.2. Experimental procedure in rats
2.2.1. Experiments to evaluate the antihypertensive
activity. In this study, we have used thirty 17–22 week-old
male SHR, weighing 314 ± 3 g, and ten 17–22 week-old male
WKY rats, weighing 337 ± 6 g. All these animals were obtained
from Charles River Laboratories España S.A. They were caged
in groups of five rats at a temperature of 23 °C with 12 hour
light/dark cycles, and they consumed tap water and a standard
diet for rats (A04 Panlab, Barcelona, Spain), ad libitum, during
the experiments.
The assayed flavan-3-ols were orally administered by gastric
intubation to the rats and tentative trials were formerly carried
out in order to estimate the doses of each monomer that could
be eﬃcient in the SHR. In accordance with these initial
trials, we evaluated the eﬀect of four diﬀerent doses of
(−)-epicatechin (1 mg kg−1, 2 mg kg−1, 6 mg kg−1 and 12 mg
kg−1), four diﬀerent doses of (+)-catechin (0.25 mg kg−1,
0.5 mg kg−1, 1.5 mg kg−1 and 3 mg kg−1) and four diﬀerent
doses of (−)-catechin (0.25 mg kg−1, 0.5 mg kg−1, 1.5 mg kg−1
and 3 mg kg−1) in the SHR. Each flavan-3-ol was evaluated by
using a minimum of 8 rats and we have always administered
increasing doses in the same animal by waiting for at least 4
days between the administrations of two diﬀerent doses. The
most eﬀective dose to lower the arterial blood pressure in the
SHR of each flavan-3-ols [6 mg kg−1 (−)-epicatechin, 0.5 mg
kg−1 (+)-catechin and 0.5 mg kg−1 (−)-catechin], was also admi-
nistered to WKY rats. In all cases, 1 ml of the corresponding
solution was orally administered by gastric intubation,
between 9 and 10 a.m. to the rats. Captopril (50 mg kg−1), a
known antihypertensive drug, served as the positive control,
and 1 ml 10% DMSO water solution served as the negative
control. We measured the SBP of the rats by the tail cuﬀ
method22 before administration and also 2, 4, 6, 8, 24, 48 and
72 hours post-administration. Before the measurement, the
rats were maintained at 30 °C for 10 minutes to make the pul-
sations of the tail artery detectable. The person who measured
the arterial blood pressure in the animals did not know either
the compound or the dose that had been administered.
2.2.2. Experiments for plasma determination. Fourteen
17–22 week-old male SHR were used for an additional study
that was carried out in order to quantify the corresponding
flavan-3-ol compound and its main metabolites in plasma, as
well as for modification of the plasma antioxidant capacity,
after flavan-3-ol administration. For these purposes, the flavan-
3-ols were orally administered by gastric intubation, as in the
arterial blood pressure trials. Determination was made in the
plasma of the rats that had been treated with the most
eﬀective dose of each flavan-3-ol, at the moment of maximum
SBP decrease [6 hours after 6 mg kg−1 (−)-epicatechin; 4 hours
after 0.5 mg kg−1 (+)-catechin and 6 hours after 0.5 mg kg−1
(−)-catechin]. Determination was also made in the plasma of
the rats treated with the highest dose of each flavan-3-ol, at the
moment of maximum decrease in SBP and also 72 hours post-
administration, when SBP had always returned to baseline
values [4 and 72 hours after 12 mg kg−1 (−)-epicatechin; 6 and
72 hours after 3.0 mg kg−1 (+)-catechin; 6 and 72 hours after
3.0 mg kg−1 (+)-catechin]. Blood samples were obtained from
the saphenous vein by using heparin vials (Starsted, Barcelona,
Spain), and the corresponding plasma samples were obtained
by centrifugation (2000g, 15 min, 4 °C). They were stored at
−80 °C until chromatographic or plasma antioxidant capacity
analysis.
2.3. Plasma determination
2.3.1 Plasma flavan-3-ol extraction and quantification.
Quantification of flavan-3-ols and their metabolites in plasma
was carried out by High-Performance Liquid Chromatography/
Electrospray Ionization coupled with tandem Mass Spectro-
metry (HPLC-ESI-MS/MS). Plasma samples were first centri-
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fuged (2000g, 5 min, 4 °C) and the plasma flavan-3-ols and
their metabolites were extracted by the oﬀ-line μ-solid phase
extraction methodology, previously described by Margalef et al.
in 2014,23 using 30 μm OASIS HLB μElution Plates (Waters,
Barcelona, Spain). Briefly, the micro-cartridges were sequen-
tially conditioned with 250 μl of methanol and 250 μl of 0.2%
acetic acid. Plasma (250 μl) was mixed with 300 μl of 4% phos-
phoric acid and 50 μl of pyrocatechol (2000 ppb), and then
loaded onto the plate. The plates were washed with 200 μl of
Milli-Q water and 200 μl of 0.2% acetic acid. The retained
flavan-3-ols and their metabolites were eluted with 2 × 50 μl
of an acetone/Milli-Q water/acetic acid (70 : 29.5 : 0.5, v : v : v)
solution. The eluted solutions were then directly injected
into the HPLC tandem triple quadrupole mass spectrometer
(HPLC-MS/MS) for chromatographic analysis.
The chromatographic analysis was performed using a 1290
Infinity UHPLC coupled with a 6490 QqQ/MS (Agilent Techno-
logies, Palo Alto, CA, USA). The separations were achieved by
using a Zorbax SB-Aq (150 mm × 2.1 mm i.d., 3.5 μm of par-
ticle size) as a chromatographic column from Agilent Techno-
logies. The mobile phase consisted of 0.2% acetic acid (solvent
A) and acetonitrile (solvent B) at a flow rate of 0.4 ml min−1.
The elution gradient was 0–10 min, 5–55% B; 10–12 min,
55–80% B; 12–15 min, 80% B isocratic; 15–16 min 80.5% B. A
post run of 10 min was applied. The sample volume injected
was 2.5 μl. The electrospray ionisation (ESI) conditions were:
150 °C and 14 l min−1 of drying gas temperature and flow,
respectively, a nebulizer gas pressure of 30 psi, and 3000 V of
capillary voltage. MS/MS was operated in a negative mode. MS/
MS acquisition was performed in a multiple reaction monitor-
ing (MRM) mode for flavan-3-ols and their metabolites, using
the same quantification previously reported by Serra et al.
(2009).24 Data acquisition was conducted by using the Mass-
Hunter software (Agilent Technologies, Palo Alto, CA, USA).
Spiked blank plasmas with standard compounds at 8
diﬀerent concentrations were used to obtain calibration curves
for quantification. Standard compounds in the samples were
quantified by interpolating the analyte/IS peak abundance
ratio in these curves. (−)-Epicatechin, (+)-catechin and
(−)-catechin metabolites were tentatively quantified by using the
standard (−)-epicatechin and (+)-catechin calibration curves
respectively. The sensitivity was evaluated by determining the
limit of detection (LOD), which is defined as the concentration
that corresponds to three times the signal-to-noise ratio, and
the limit of quantification (LOQ), which is defined as the con-
centration that corresponds to 10 times the signal-to-noise
ratio. The method detection and quantification limits (MDL
and MQL, respectively) were calculated in the analysis of 250 μl
of a sample. Table 1 shows the values that were obtained for
each quality parameter.
2.3.2. Plasma antioxidant capacity. To measure the
plasma antioxidant capacity we used the oxygen radical absor-
bance capacity (ORAC) assay, as previously described by Huang
et al.25 Briefly, 25 μl of plasma solution and 150 μl of 59.8 nM
fluorescein (FL) (Sigma-Aldrich) were added to each well of a
96-well microplate. The fluorescence was measured at λex =
485 nm and λem = 520 nm every min for 90 min in the FLx800
Multi-Detection Microplate Reader (Biotek, Winooski, USA)
after the addition by using an injector of 25 μl of 73 mM of the
radical generator 2,2′-azobis(2-methylpropionamidine)dihydro-
chloride (AAPH, Acros Organics, Belgium). As a standard,
Trolox (Sigma-Aldrich) solution was used at diﬀerent concen-
trations (0, 3.125, 6.25, 12.5, 25, 50, and 100 μM). The final
ORAC values were calculated by a regression equation between
the Trolox concentration and the net area under the FL decay
curve and were expressed as μmol Trolox equivalents (TE)ml−1.
All the above-mentioned experiments were designed and
performed in accordance with the European and Spanish legis-
lation on care and use of experimental animals (2010/63/UE;
Real Decreto 53/2013), and were approved by the Ethics Com-
mittees at Universidad Complutense de Madrid (UCM).
2.4. Statistical analysis
SBP results are expressed as mean values ± standard error of
the mean (SEM) for a minimum of 8 rats and the plasma
results are expressed as mean values ± SEM for a minimum of
6 rats. They were analyzed by a one- or two-way analysis of var-
iance (ANOVA), using the GraphPad Prism 4 software in the
case of SBP values, and using the SPSS software (Version
20.0.0) in the case of plasma values. The diﬀerences between
the groups were assessed by the Bonferroni test and the diﬀer-
ences were always considered to be significant when p < 0.05.
3. Results
Before administration of the diﬀerent products, the SHR
showed SBP values of 236 ± 2.5 mmHg; n = 30. The values of
Table 1 Calibration curve, determination coeﬃcient (R2) and limits of quantiﬁcation and detection, for the quantiﬁcation of ﬂavan-3-ols in the
spiked plasma samples by High-Performance Liquid Chromatography/Electrospray Ionization coupled with tandem Mass Spectrometry
Compound
Calibration
curve R2
LOD
(μM)
LOQ
(μM)
MDL
(μM)
MQL
(μM)
(+)-Catechin y = 0.0159x 0.992 0.003 0.009 0.001 0.003
(−)-Epicatechin y = 0.0179x 0.993 0.002 0.008 0.001 0.003
Abbreviations: LOD (limit of detection); LOQ (limit of quantification); MDL (method detection limit); MQL (method quantification limit). The
(+)-catechin calibration curve was used to quantify catechin and its metabolites and the (−)-epicatechin calibration curve was used to quantify
(−)-epicatechin and its metabolites.
Food & Function Paper
This journal is © The Royal Society of Chemistry 2015 Food Funct., 2015, 6, 3479–3489 | 3481
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
3/
03
/2
01
7 
18
:1
0:
17
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
SBP obtained after the oral administration of 1 ml of 10%
DMSO solution (used as the negative control), were very similar
to those obtained before its administration. On the contrary,
the dose of 50 mg kg−1 of Captopril (used as the positive
control) caused a clear decrease in SBP in the SHR. The
maximum decrease in SBP caused by this drug (60.5 ±
2.7 mmHg) was observed 4 hours post-administration, and this
variable returned to the baseline 48 hours post-administration.
The oral administration of (−)-epicatechin also resulted in a
significant decrease of the SBP in the SHR. The maximum
eﬀect was attained 6–8 hours post-administration of 6 mg kg−1
of this flavan-3-ol. The decreases of SBP at that moment were,
respectively, 34.0 ± 4.8 mmHg and 34.3 ± 5.6 mmHg, and
SBP remained still lower than the basal SBP value when
measurements were made 48 hours post-administration of
(−)-epicatechin. Nevertheless, the values of SBP obtained
72 hours post-administration of this flavan-3-ol were similar to
those obtained before the administration (Fig. 1A). The admin-
istration of (+)-catechin also caused a significant decrease in
the SBP of the SHR, and the decrease was maximum 4 hours
post-administration of 0.5 mg kg−1 of this flavan-3-ol (29.9 ±
0.8 mmHg). SBP returned to the baseline 48 hours post-admin-
istration of this dose of (+)-catechin (Fig. 2A). The adminis-
tration of (−)-catechin also caused a significant decrease in the
SBP of the SHR. Nevertheless, the eﬀect of this flavan-3-ol
on this variable was less accentuated than the eﬀect of
(−)-epicatechin or (+)-catechin. The more eﬀective dose of
(−)-catechin was 0.5 mg kg−1, and the maximum decrease in
SBP caused by this dose of this flavan-3-ol was observed
6–8 hours post-administration. At that moment, the decreases in
SBP were, respectively, 23.6 ± 5.9 mmHg and 24.5 ± 5.7 mmHg.
In addition, we could observe that, 72 hours post-administration
of 0.5 mg kg−1 of (−)-catechin, the values of SBP were already
similar to those obtained before administration (Fig. 3A).
None of the assayed flavan-3-ols modified SBP in the WKY
rats. This variable was similar in the WKY rats that were
treated with these products and in the WKY rats that were
treated with the 10% DMSO solution (Fig. 1B, 2B and 3B).
Fig. 4 shows the diﬀerent flavan-3-ol signals obtained in the
chromatographic analysis of plasma samples. This analysis
Fig. 1 (A) Decreases in systolic blood pressure (SBP) caused in spontaneously hypertensive rats by the negative control (○), Captopril (50 mg kg−1)
(□) or diﬀerent doses of (−)-epicatechin: 1 mg kg−1 (◆), 2 mg kg−1 (▲), 6 mg kg−1 (●) and 12 mg kg−1 (■). (B) Decreases in SBP caused in Wistar-Kyoto
rats by the negative control (○) or 6 mg kg−1 (−)-epicatechin (●). Data are expressed as mean ± SEM. The experimental groups always have a
minimum of 8 animals. Diﬀerent letters represent the statistical diﬀerences (p < 0.05). p estimated by two-way ANOVA.
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revealed only glucuronide metabolites and methyl-glucuronide
metabolites, apart from the original flavan-3-ols, as all other
potential phase II metabolites, as sulfated and methylated
derivatives, were not detected. In detail, the following concrete
metabolites were detected: epicatechin glucuronide, methyl-
epicatechin glucuronide, catechin glucuronide and methyl-
catechin glucuronide. Fig. 5 shows the concentration of the all
these flavan-3-ol compounds, that had been detected in the
plasma after the diﬀerent administrations. As this figure
shows, scarce concentrations of unconjugated flavan-3-ols
appeared in the plasma of the treated rats, regardless of the
administered dose and the time elapsed after the treatment.
On the contrary, methyl-glucuronide metabolites were always
obtained in this biological fluid after diﬀerent treatments. Sig-
nificant concentrations of the glucuronide metabolite were
appreciated after 6 mg kg−1 (−)-epicatechin administration,
but these conjugated products did not appear in the plasma
when the most eﬀective doses of the other flavan-3-ols
were administered (0.5 mg kg−1 (+)-catechin or 0.5 mg kg−1
(−)-catechin). However, glucuronide metabolites were obtained
when the highest doses of the diﬀerent flavan-3-ols (12 mg kg−1
(−)-epicatechin, 3 mg kg−1 (+)-catechin or 3 mg kg−1 (−)-catechin)
were administered, being the concentration of the glucuronide
metabolite particularly high after the administration of 12 mg
kg−1 (−)-epicatechin. In any case, no correlation could be
established between the plasma concentration of glucuronide
and/or methyl-glucuronide metabolites, and the antihyperten-
sive eﬀect caused in the animals by (−)-epicatechin or the
catechin monomers. 72 hours post-flavan-3-ol administration,
neither flavan-3-ol compounds nor flavan-3-ol metabolites
could be detected in plasma (data not shown).
As panel A in Fig. 6 shows, no diﬀerences were observed in
the plasma antioxidant capacity between the rats administered
with 10% DMSO solution and the rats administered with more
eﬀective antihypertensive doses of the diﬀerent flavan-3-ols
(6 mg kg−1 (−)-epicatechin, 0.5 mg kg−1 (+)-catechin or 0.5 mg
kg−1 (−)-catechin). Nevertheless, as panel B in Fig. 6 shows,
the administration of the highest doses of the diﬀerent flavan-
Fig. 2 (A) Decreases in systolic blood pressure (SBP) caused in spontaneously hypertensive rats by the negative control (○), Captopril (50 mg kg−1)
(□) or diﬀerent doses of (+)-catechin: 0.25 mg kg−1 (◆), 0.5 mg kg−1 (▲), 1.5 mg kg−1 (●) and 3 mg kg−1 (■). (B) Decreases in SBP caused in Wistar-
Kyoto rats by the negative control (○) or 0.5 mg kg−1 (+)-catechin (▲). Data are expressed as mean ± SEM. The experimental groups always have a
minimum of 8 animals. Diﬀerent letters represent the statistical diﬀerences (p < 0.05). p estimated by two-way ANOVA.
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3-ols (12 mg kg−1 (−)-epicatechin, 3 mg kg−1 (+)-catechin or
3 mg kg−1 (−)-catechin) caused always an increase in the
plasma antioxidant capacity in the rats.
4. Discussion
SHR are frequently used to carry out initial studies with
antihypertensive functional food ingredients because these
animals represent nowadays the best experimental model for
essential hypertension in humans.26 In the present study, we
have demonstrated that the short-term administration of
(−)-epicatechin and (+)-catechin, two flavan-3-ols present
in cocoa and other diﬀerent foods, decreased SBP in SHR.
(−)-Catechin, an atypical flavan-3-ol produced by changes in
the chiral nature of (−)-epicatechin during the cocoa manufactur-
ing process,12 also decreased the arterial blood pressure in
this strain. On the contrary, none of these flavan-3-ols
decreased SBP in the normotensive WKY rats. The arterial
blood pressure eﬀects of the assayed flavan-3-ols are therefore
specific for the hypertensive condition.
The healthy properties of cocoa seem to be related to its
high content in monomeric, dimeric and potentially polymers
of flavan-3-ols.27 (−)-Epicatechin is the most abundant
monomer in cocoa seeds and cocoa derived foods. In accord-
ance with the results that we have obtained in SHR, a recent
study has demonstrated that the long-term administration of
10 mg kg−1 (−)-epicatechin prevented deoxycorticosterone
acetate-salt induced hypertension in rats.28 The high amount
of (−)-epicatechin in cocoa seems actually to be important,
because, in previous studies an increased plasma level of
this flavan-3-ol was accompanied by a dose-dependent increase
in the plasma antioxidant capacity,29,30 and also with a
dose-dependent decrease in plasma lipid oxidation29 and
a beneficial eﬀect on the vascular function.31 Moreover,
(−)-epicatechin decreases serum oxidative stress8 and restores
Fig. 3 (A) Decreases in systolic blood pressure (SBP) caused in spontaneously hypertensive rats by the negative control (○), Captopril (50 mg kg−1)
(□) or diﬀerent doses of (−)-catechin: 0.25 mg kg−1 (◆), 0.5 mg kg−1 (▲), 1.5 mg kg−1 (●) and 3 mg kg−1 (■). (B) Decreases in SBP caused in Wistar-
Kyoto rats by the negative control (○) or 0.5 mg kg−1 (−)-catechin (▲). Data are expressed as mean ± SEM. The experimental groups always have a
minimum of 8 animals. Diﬀerent letters represent the statistical diﬀerences (p < 0.05). p estimated by two-way ANOVA.
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Fig. 4 Multiple reaction monitoring (MRM) signals of the compounds found in the plasma of spontaneously hypertensive rats after oral adminis-
tration of diﬀerent ﬂavan-3-ols: (A) 6 hours after oral administration of 6 mg kg−1 (−)-epicatechin. (B) 4 hours after oral administration of 0.5 mg kg−1
(+)-catechin. (C) 6 hours after oral administration of 0.5 mg kg−1 (−)-catechin. The following compounds were obtained: (−)-epicatechin (1), methyl-
epicatechin glucuronide (2), epicatechin glucuronide (3), catechin (4), methyl-catechin glucuronide (5), catechin glucuronide (6) and catechin (7).
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the NO bioavailability.32 In addition, a study of our research
group has also demonstrated the participation of NO in the
antihypertensive eﬀect of a polyphenol-rich cocoa in SHR.33
(+)-Catechin predominates in cocoa beans and (−)-catechin
in chocolate, and it has been postulated that (+)-catechin is
almost 10 times more absorbed than (−)-catechin.12 In this
study, the administration of (+)-catechin, and also the adminis-
tration of (−)-catechin, caused a significant decrease in the
SBP of the SHR. Nevertheless, the eﬀect of (−)-catechin on this
variable was less accentuated than the eﬀect of (−)-epicatechin
or (+)-catechin. In the last few years, an important role has
been attributed to the chiral nature of polyphenols and the
eﬀects of chirality on bioavailability. Ottaviani et al. have
demonstrated the significance of the stereochemical configur-
ation of flavan-3-ols for their biological activity.34 These facts
may explain why catechin from processed cocoa [mainly
(−)-catechin], is not as well absorbed as (+)-catechin.35 In any
case, in this study, the eﬀects of (+)-catechin in SHR, and the
eﬀects of (−)-catechin in these animals were not very diﬀerent,
and the metabolites of both catechin monomers in the plasma
of the treated rats were also very similar, indicating a similar
oral absorption of these two isomers. The eﬀect seems
however to last somewhat more when (−)-catechin was admi-
nistered and we shall comment on this later.
It is therefore clear that all the flavan-3-ols assayed showed
a blood pressure lowering eﬀect in the SHR, and, this study
enables us to characterize and to compare their antihyperten-
sive eﬀect in these animals. Among the three used flavan-3-ols,
(−)-epicatechin was the most eﬀective one, even if (+)-catechin
and (−)-catechin were more potent than (−)-epicatechin
to decrease the arterial blood pressure in the SHR. In
fact, maximum decreases in SBP were obtained when
(−)-epicatechin was administered, but lower doses of (+)-catechin
and (−)-catechin were needed for the antihypertensive eﬀect. It
is also important to highlight that in this study we failed to
demonstrate a dose-dependent antihypertensive eﬀect for the
three monomers that we have used. In fact, the maximum
eﬀect was attained always with a dose diﬀerent form the
Fig. 5 Concentration of the ﬂavan-3-ol compounds in plasma samples of spontaneously hypertensive rats: 6 hours after oral administration of
6 mg kg−1 (−)-epicatechin (panel A); 4 hours after oral administration of 12 mg kg−1 (−)-epicatechin (panel B); 4 hours after oral administration of
0.5 mg kg−1 (+)-catechin (panel C); 6 hours after oral administration of 3 mg kg−1 (+)-catechin (panel D); 6 hours after oral administration of 0.5 mg
kg−1 (−)-catechin (panel E); 6 hours after oral administration of 3 mg kg−1 (−)-catechin (panel F). Data are expressed as mean (μM) ± SEM. The experi-
mental groups always have a minimum of 6 animals.
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highest one (6 mg kg−1 of (−)-epicatechin, 0.5 mg kg−1 of
(+)-catechin and 0.5 mg kg−1 of (−)-catechin). A similar paradox
was observed when we had administered a polyphenol-rich
cocoa powder in SHR, since the maximum antihypertensive
eﬀect in these animals was neither obtained when we adminis-
tered the highest dose of this cocoa powder.9 The results
obtained by our research group using both the cocoa mono-
mers and the cocoa powder are somewhat diﬃcult to under-
stand. They might be explained by keeping in mind diﬀerent
studies that demonstrated that a high quantity of polyphenols
could exhibit pro-oxidant properties instead of antioxidant
properties.36,37 It is true that, in the present study, an increase
in the dose of the assayed flavan-3-ols was related to an
increased plasma antioxidant capacity, but the plasma anti-
oxidant capacity cannot totally define the endothelium redox
status. An improved vascular oxidative stress in the SHR
treated with the most eﬀective doses of the assayed flavan-3-
ols, or a pro-oxidant eﬀect on arterial tissue in the rats pre-
Fig. 6 Oxygen radical absorbance capacity (ORAC) histograms of plasma samples from spontaneously hypertensive rats. Panel A: 4 hours after oral
administration of 10% DMSO solution (control group) (■), 6 hours after oral administration of 6 mg kg−1 (−)-epicatechin ( ), 4 hours after oral admin-
istration of 0.5 mg kg−1 (+)-catechin ( ) and 6 hours after oral administration of 0.5 mg kg−1 of (−)-catechin (□). Panel B: 4 hours after oral adminis-
tration of 10% DMSO solution (control group) (■), 4 hours after oral administration of 12 mg kg−1 (−)-epicatechin ( ), 6 hours after 3 mg kg−1
(+)-catechin ( ) and 6 hours after oral administration of 3 mg kg−1 of (−)-catechin (□). Data are expressed as mean (μmol TE ml−1) ± SEM. The experi-
mental groups always have a minimum of 6 animals. Diﬀerent letters represent the statistical diﬀerences (p < 0.05). p estimated by two-way ANOVA.
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viously treated with the highest doses of these compounds,
cannot be ruled out. In addition, it is also important to bear in
mind that other properties of the assayed flavan-3-ols could
explain their blood pressure eﬀects. In this context, activation
of the deacetylase sirtuin 1 (SIRT1) and up-regulation of endo-
thelial nitric oxide synthase38,39 have also been proposed to
explain the cardiovascular eﬀects of polyphenols. Moreover,
the eﬀects of polyphenols have also been attributed to the
induction of antioxidant enzymes in cardiovascular tissues40,41
and also to the inhibition of the angiotensin converting enzyme.42
On seeing the period of time elapsed to recover the baseline
values of SBP from administration, we can also assume that
the eﬀects of (−)-epicatechin and (−)-catechin (Fig. 1A and 3A)
were longer than the antihypertensive eﬀect of (+)-catechin
(Fig. 2A). The in vivo bioactivity of the flavan-3-ols depends on
their process of absorption and metabolism after ingestion,
and the reducing properties of resulting metabolites. The
highest plasma peak concentrations of flavan-3-ols in humans
are obtained 2–3 hours after ingestion of these compounds29,30
and they are still measurable after 8 hours.43 Nevertheless, it is
important to note that in this study the metabolite profile has
been performed for 4 and 6 h in order to evaluate the bioavail-
able plasma metabolites at the maximum blood pressure
decrease time point. In this study, the eﬀect of (−)-epicatechin,
(+)-catechin and (−)-catechin could also be appreciated
8 hours post-administration. It should be noted that
(−)-epicatechin and (+)-catechin in particular, showed a good
bioavailability in humans.13 Flavan-3-ols are conjugated after
ingestion by phase-II enzymes in the small intestine and liver,
and it has been demonstrated that some of the beneficial
eﬀects of these compounds are due to the metabolized
forms.14 Even if (−)-epicatechin and catechin monomers are
usually conjugated to produce sulphate, glucuronide and
methyl-glucuronide metabolites,14,44 in this study, only glucur-
onide and methyl-glucuronide metabolites were quantified in
the plasma from the treated rats. These metabolites, but not
sulphate metabolites, could therefore be responsible for the
antihypertensive eﬀects of the assayed flavan-3-ols. At first
sight, the products enriched in these monomers might rep-
resent a good strategy in biomedicine, but it is nevertheless
true that no correlation could be established in our study
between the plasma concentration of the glucuronide and
methyl-glucuronide metabolites, and the antihypertensive
eﬀect caused by the (−)-epicatechin or the catechin monomers.
Thus, when the most eﬀective doses of these flavan-3-ols were
administered, we did not obtain the highest concentration of
these metabolites. Moreover, the administration of the most
eﬀective doses of the catechin monomers (0.5 mg kg−1 for
both catechin monomers) were not accompanied with gluc-
uronide metabolites in plasma, and this suggests that methyl-
glucuronide metabolites could actually be responsible for the
eﬀect of the catechin monomers. Glucuronide metabolites
appeared nevertheless in the plasma obtained from the rats
that were treated with the highest dose of these monomers,
and also in all the plasma samples from the (−)-epicatechin
treated rats, but the concentration of the (−)-epicatechin glu-
curonide metabolite was also lower in the plasma of the
rats treated with the most eﬀective antihypertensive dose of
(−)-epicatechin (6 mg kg−1) than in the plasma obtained from
the rats that had been treated with the highest dose of this
flavan-3-ol (12 mg kg−1). It seems in addition that according to
our results, the eﬀect of the assayed flavan-3-ols was always
elapsed 72 hours after their administration and that at this
time no flavan-3-ol metabolites were present in the plasma of
the rats.
In conclusion, we have demonstrated the antihypertensive
properties of the main cocoa flavan-3-ols in SHR and we have
also demonstrated that the eﬀect of the evaluated monomers
is specific to the hypertensive conditions. Therefore, the
flavan-3-ols (−)-epicatechin and (+)-catechin, and also the aty-
pical epimer (−)-catechin, would be beneficial for controlling
arterial blood pressure. They could be responsible for the anti-
hypertensive eﬀect of diﬀerent cocoa powders and functional
foods. The present study also represents a good contribution to
clarify the metabolites generated in the SHR when these flavan-
3-ols are administered to these animals. Nevertheless, our
results neither enable us to relate the antihypertensive eﬀect of
the assayed flavan-3-ols with the presence of a concrete flavan-3-
ol metabolite in plasma, nor to consider the antioxidant eﬀect
of the used flavan-3-ols as their main antihypertensive mechan-
ism. The concentration of flavan-3-ol metabolites in arterial
tissues may provide interesting information in the future to elu-
cidate their cardiovascular role, and further research should be
interesting to go deep into the mechanisms that could explain
the antihypertensive eﬀects of the assayed flavan-3-ols.
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